PorA variable antigenic regions VR1, VR2, and VR3 of Neisseria meningitidis serogroups B and C isolated in Brazil from 1999 to 2004

Infection and Immunity

Volumn 75, Issue 7, 2007, Pages 3683-3685

  De Filippis, Ivano ^a,b   De Andrade, Claudia Ferreira ^a   Silva, Luciete ^c   Prevots, D Rebecca ^b   Vicente, Ana Carolina P ^d  

^a Oswaldo Cruz Foundation   (Brazil)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c INSTITUTO LEÔNIDAS E MARIA DEANE   (Brazil)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MENINGOCOCCUS VACCINE; PORIN A;

AMINO ACID SEQUENCE; ARTICLE; BACTERIUM CARRIER; BRAZIL; GENETIC VARIABILITY; GENOTYPE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANTIGENIC VARIATION; BRAZIL; CARRIER STATE; CEREBROSPINAL FLUID; HUMANS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL INFECTIONS; MOLECULAR SEQUENCE DATA; NASOPHARYNX; NEISSERIA MENINGITIDIS, SEROGROUP B; NEISSERIA MENINGITIDIS, SEROGROUP C; PORINS; SEQUENCE ANALYSIS, DNA;

EID: 34447291124     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.01721-06     Document Type: Article

References (24)

1. Arhin, F. F., F. Moreau, J. W. Coulton, and E. L. Mills. 1998. Sequencing of porA from clinical isolates of Neisseria meningitidis defines a subtyping scheme and its genetic regulation. Can. J. Microbiol. 44:56-63.
2. Bjune, G., E. A. Hoiby, J. K. Gronnesby, O. Arnesen, J. H. Fredriksen, A. Halstensen, E. Holten, A. K. Lindbak, H. Nokleby, E. Rosenqvist, et al. 1991. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338:1093-1096.
3. Boslego, J., J. Garcia, C. Cruz, W. Zollinger, B. Brandt, S. Ruiz, M. Martinez, J. Arthur, P. Underwood, W. Silva, E. Moran, W. Hankins, J. Gilly, J. Mays, and the Chilean National Committee for Meningococcal Disease. 1995. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine 13:821-829.
4. Cartwright, K. A. V., R. Morris, H. Ruemke, A. Fox, R. Borrow, N. Begg, P. Richmond, and J. Poolman. 1999. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 outer membrane proteins. Vaccine 17:2612-2619.
5. Christodoulides, M., B. T. McGuinness, and J. E. Heckels. 1993. Immunization with synthetic peptides containing epitopes of the class 1 outer-membrane protein of Neisseria meningitidis: production of bactericidal antibodies on immunization with a cyclic peptide. J. Gen. Microbiol. 139:1729-1738.
6. Clarke, S. C., M. A. Diggle, and G. F. Edwards. 2001. Semiautomation of multilocus sequence typing for the characterization of clinical isolates of Neisseria meningitidis. J. Clin. Microbiol. 39:3066-3071.
7. Clarke, S. C., M. A. Diggle, P. Molling, M. Unemo, and P. Olcen. 2003. Analysis of PorA variable region 3 in meningococci: implications for vaccine policy? Vaccine 21:2468-2473.
8. de Filippis, I., and A. C. Vicente. 2005. Multilocus sequence typing and repetitive element-based polymerase chain reaction analysis of Neisseria meningitidis isolates in Brazil reveal the emergence of 11 new sequence types genetically related to the ST-32 and ST-41/44 complexes and high prevalence of strains related to hypervirulent lineages. Diagn. Microbiol. Infect. Dis. 53:161-167.
9. de Moraes, C. J., B. A. Perkins, M. C. Camargo, N. T. Hidalgo, H. A. Barbosa, C. T. Sacchi, I. M. Landgraf, V. L. Gattas, and H. G. Vasconcelos. 1992. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 340:1074-1078.
10. Diggle, M. A., and S. C. Clarke. 2003. Detection and genotyping of meningococci using a nested PCR approach. J. Med. Microbiol. 52:51-57.
11. Feavers, I. M., and M. C. Maiden. 1998. A gonococcal porA pseudogene: implications for understanding the evolution and pathogenicity of Neisseria gonorrhoeae. Mol. Microbiol. 30:647-656.
12. Findlow, J., S. Taylor, A. Aase, R. Horton, R. Heyderman, J. Southern, N. Andrews, R. Barchha, E. Harrison, A. Lowe, E. Boxer, C. Heaton, P. Balmer, E. Kaczmarski, P. Oster, A. Gorringe, R. Borrow, and E. Miller. 2006. Comparison and correlation of Neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac. Infect. Immun. 74:4557-4565.
13. Martin, S. L., R. Borrow, P. van der Ley, M. Dawson, A. J. Fox, and K. A. Cartwright. 2000. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine. Vaccine 18:2476-2481.
14. Molling, P., M. Unemo, A. Backman, and P. Olcen. 2000. Genosubtyping by sequencing group A, B and C meningococci; a tool for epidemiological studies of epidemics, clusters and sporadic cases. APMIS 108:509-516.
15. Oomen, C. J., P. Hoogerhout, A. M. Bonvin, B. Kuipers, H. Brugghe, H. Timmermans, S. R. Haseley, L. van Alphen, and P. Gros.2003. Immunogenicity of peptide-vaccine candidates predicted by molecular dynamics simulations. J. Mol. Biol. 328:1083-1089.
16. Oomen, C. J., P. Hoogerhout, B. Kuipers, G. Vidarsson, L. van Alphen, and P. Gros. 2005. Crystal structure of an anti-meningococcal subtype P1.4 PorA antibody provides basis for peptide-vaccine design. J. Mol. Biol. 351:1070-1080.
17. Oster, P., D. Lennon, J. O'Hallahan, K. Mulholland, S. Reid, and D. Martin. 2005. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 23:2191-2196.
18. Peeters, C. C., I. J. Claassen, M. Schuller, G. F. Kersten, E. M. van der Voort, and J. T. Poolman. 1999. Immunogenicity of various presentation forms of PorA outer membrane protein of Neisseria meningitidis in mice. Vaccine 17:2702-2712.
19. Riesbeck, K., P. Orvelid-Molling, H. Fredlund, and P. Olcen. 2000. Long-term persistence of a discotheque-associated invasive Neisseria meningitidis group C strain as proven by pulsed-field gel electrophoresis and porA gene sequencing. J. Clin. Microbiol. 38:1638-1640.
20. Russell, J. E., K. A. Jolley, I. M. Feavers, M. C. Maiden, and J. Suker. 2004. PorA variable regions of Neisseria meningitidis. Emerg. Infect. Dis. 10:674-678.
21. Sierra, G. V. G., H. C. Campa, N. W. Varcacel, I. L. Garcia, P. L. Izquierdo, P. F. Sotolongo, G. V. Casanueva, C. O. Rico, C. R. Rodriguez, and M. H. Terry. 1991. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 14:195-207.
22. Tappero, J. W., R. Lagos, A. M. Ballesteros, B. Plikaytis, D. Williams, J. Dykes, L. L. Gheesling, G. M. Carlone, E. A. Hoiby, J. Holst, H. Nokleby, E. Rosenqvist, G. Sierra, C. Campa, F. Sotolongo, J. Vega, J. Garcia, P. Herrera, J. T. Poolman, and B. A. Perkins. 1999. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 281:1520-1527.
23. Urwin, R., J. E. Russell, E. A. Thompson, E. C. Holmes, I. M. Feavers, and M. C. Maiden. 2004. Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect. Immun. 72: 5955-5962.
24. van der Ley, P., J. E. Heckels, M. Virji, P. Hoogerhout, and J. T. Poolman. 1991. Topology of outer membrane porins in pathogenic Neisseria spp. Infect. Immun. 59:2963-2971.